In the realm of mental health treatment, antipsychotic medications play a crucial role in managing conditions such as schizophrenia and bipolar disorder. However, these medications are not without their drawbacks, particularly in terms of cardiovascular health. Patients using antipsychotics face an elevated risk of developing cardiovascular diseases, a concern that necessitates rigorous management and monitoring. Despite this, general practice often lacks robust cardiovascular risk management strategies tailored specifically for this group. In light of these challenges, a ground-breaking feasibility study has emerged, exploring the implementation of TACTIC—a person-centred, multidisciplinary programme aimed at reducing cardiovascular risk among antipsychotic users.

Understanding the TACTIC Programme

TACTIC, short for Targeted Antipsychotic-Centric Intervention for Cardiovascular Health, is designed to address the unique needs of patients on antipsychotic medication. The programme is built upon a multidisciplinary approach, involving general practitioners, psychiatrists, and other healthcare professionals. It focuses on a comprehensive review of antipsychotic medication use while simultaneously implementing strategies to mitigate cardiovascular risk.

Exploring Barriers and Facilitators

The feasibility study, conducted across three Dutch general practices, sought to identify the barriers and facilitators associated with delivering the TACTIC intervention. Through eight individual interviews with patients and two focus group discussions with healthcare professionals, several key insights emerged:

• Barriers: Patients reported experiencing tension related to their participation in the programme. Additionally, the multidisciplinary meetings were sometimes perceived as cumbersome, and general practitioners noted a high workload as a significant challenge.
• Facilitators: The person-centred approach of TACTIC was widely appreciated. Clear information meetings and the flexibility in adjusting roles within the intervention were seen as major strengths.

Suggestions for Improvement

To optimise the TACTIC programme before its evaluation in a larger randomised controlled trial, several valuable suggestions were made:

• Introduce a summary report from psychiatrists to provide a clearer overview of patient progress.
• Improve expectation management for patients to reduce anxiety and enhance engagement.
• Refine the definition of the target group to ensure that those most at risk are prioritised.

Conclusion

The findings underscore the importance of conducting feasibility studies before launching full-scale trials. By identifying and addressing potential barriers, and leveraging facilitators, the effectiveness and implementability of interventions like TACTIC can be significantly enhanced. As we move towards a future where mental and cardiovascular health are integrated seamlessly in general practice, such pioneering studies pave the way for improved patient outcomes and holistic care.

This study not only highlights the urgent need for tailored cardiovascular risk management in antipsychotic users but also exemplifies the power of collaborative, person-centred healthcare strategies. As we continue to explore innovative solutions, the ultimate goal remains clear: to safeguard the heart health of those who rely on antipsychotic medications, ensuring they receive the comprehensive care they deserve.

Source: Cardiovascular risk management in patients using antipsychotics – a qualitative feasibility study